Aptevo Therapeutics Inc.
APVO
$1.87
-$0.01-0.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.21% | 2.32% | -1.64% | 69.00% | 21.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.49% | 5.51% | 82.50% | 45.98% | 3.35% |
| Operating Income | -3.49% | -5.51% | -82.50% | -45.98% | -3.35% |
| Income Before Tax | -2.45% | -4.51% | 8.02% | -47.99% | -5.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.45% | -4.51% | 8.02% | -47.99% | -5.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.45% | -4.51% | 8.02% | -47.99% | -5.46% |
| EBIT | -3.49% | -5.51% | -82.50% | -45.98% | -3.35% |
| EBITDA | -3.79% | -5.97% | -81.98% | -47.42% | -4.11% |
| EPS Basic | 96.49% | -- | -- | -- | -- |
| Normalized Basic EPS | 96.49% | -- | -- | -- | -- |
| EPS Diluted | 96.49% | -- | -- | -- | -- |
| Normalized Diluted EPS | 96.49% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 2,818.05% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 2,818.05% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |